(S)-4-benzyl-3-((S)-4,4,4-trifluoro-3-methylbutanoyl)oxazolidin-2-one | 952714-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-4-benzyl-3-((S)-4,4,4-trifluoro-3-methylbutanoyl)oxazolidin-2-one
• 英文别名: (4S)-4-benzyl-3-[(3S)-4,4,4-trifluoro-3-methylbutanoyl]-1,3-oxazolidin-2-one；(S)-4-benzyl-3-[(3S)-4,4,4-trifluoro-3-methyl-butanoyl]-1,3-oxazolidin-2-one；(4S)-4-benzyl-3-[(3S)-3-(trifluoromethyl)butanoyl]-1,3-oxazolidin-2-one
• CAS: 952714-68-0
• 化学式: C₁₅H₁₆F₃NO₃
• 分子量: 315.292
• InChiKey: UJGOFZSSXXMXHQ-JQWIXIFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-4-benzyl-3-((S)-4,4,4-trifluoro-3-methylbutanoyl)oxazolidin-2-one 在 三氟甲磺酸二丁硼 、 N,N-二异丙基乙胺 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 以73%的产率得到(S)-4-benzyl-3-((2S,3R)-2-bromo-4,4,4-trifluoro-3-methylbutanoyl)-oxazolidin-2-one
  参考文献：
  名称：

  Conjugate hydrotrifluoromethylation of α,β-unsaturated acyl-oxazolidinones: synthesis of chiral fluorinated amino acids

  摘要：

  描述了一种新颖的共轭氢氟烷基化α,β-不饱和酰基噁唑烷酮的方法。利用该方法，制备了手性纯的β-三氟甲基化氨基酸。三氟瓦林和三氟异亮氨酸被引入到肽中，发现其α-螺旋倾向极低。

  DOI：

  10.1039/c2ob26810h
• 作为产物：
  描述：

  (S)-4-苄基-2-唑烷酮 在 正丁基锂 、 ytterbium(III) triflate hydrate 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (S)-4-benzyl-3-((S)-4,4,4-trifluoro-3-methylbutanoyl)oxazolidin-2-one
  参考文献：
  名称：

  Conjugate hydrotrifluoromethylation of α,β-unsaturated acyl-oxazolidinones: synthesis of chiral fluorinated amino acids

  摘要：

  描述了一种新颖的共轭氢氟烷基化α,β-不饱和酰基噁唑烷酮的方法。利用该方法，制备了手性纯的β-三氟甲基化氨基酸。三氟瓦林和三氟异亮氨酸被引入到肽中，发现其α-螺旋倾向极低。

  DOI：

  10.1039/c2ob26810h

文献信息

• SPIROPYRROLIDINES AS MDM2 INHIBITORS
  申请人：HUDSON BIOPHARMA INC.

  公开号：US20150322076A1

  公开（公告）日：2015-11-12

  Described are spiropyrrolidines (I) useful as inhibitors of MDM2/p53 interactions and provides useful agents for the treatment of diseases like cancer and retinal macular degeneration diseases. The invented compounds herein have the general Further described are pharmaceutical compositions that comprise one or more compounds of the invention, a pharmaceutically acceptable salt or pro-drug and/or a pharmaceutically acceptable carrier or excipient.

  描述了作为MDM2/p53相互作用抑制剂的螺环吡咯烷(I)，并提供了用于治疗癌症和视网膜黄斑变性等疾病的有用药剂。本发明的化合物具有一般性。进一步描述了包括本发明的一个或多个化合物、药学上可接受的盐或前药以及药学上可接受的载体或赋形剂的药物组合物。
• Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
  申请人：Porte Alexander Michael

  公开号：US20070249722A1

  公开（公告）日：2007-10-25

  A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R 1 -R 7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

  提供了Formula (I)的化合物，或其药用可接受的盐和/或水合物或前药，其中Formula (I)具有以下结构： 在此定义了R1-R7。这些化合物在治疗从阿尔茨海默病、淀粉样血管病、脑淀粉样血管病、全身性淀粉样病、荷兰型遗传性脑出血伴淀粉样病、包涵体肌炎、轻度认知障碍（MCI）和唐氏综合征等疾病的药物中对受试者有用。
• Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
  申请人：Sellstedt John

  公开号：US20070249869A1

  公开（公告）日：2007-10-25

  A method of selectively preparing a chiral 2S-amino alcohol useful in preparation of an amide sulfonated or acylated with alkyl, substituted aryl or substituted heteroaryl is described. The method involves reacting a di-tert-butyl diazene-1,2-dicarboxylate with a (4S)-4-benzyl-3-[(S)-trifluoromethyl-alkyl substituted alkanoyl]-1,3-oxazolidin-2-one to afford a di-tert-butyl 1-(1S,2S)-([(4S)-4-benzyl-2-oxo-1,3-oxazolidine-3-yl]-carbonyl}-trifluoromethyl-alkyl substituted alkyl)hydrazine-1,2-dicarboxylate. This dicarboxylate is then reduced to yield di-tert-butyl 1-(1S,2S)-[trifluoromethyl-alkyl substituted alkyl]hydrazine-1-(hydroxymethyl)-1,2-dicarboxylate. The resulting product is deblocked with an acid to yield the acid addition salt of (2S,3S)-trifluoro-hydrazino-methyl alkan-1-ol. The acid addition salt of (2S,3S)-trifluor-2-hydrazino-methyl alkan-1-ol is hydrogenated in the presence of a suitable metal catalyst to yield the amino alcohol (2S,3S)-2-amino-trifluoro-methyl alkan-1-ol HCl.

  描述了一种选择性制备手性2S-氨基醇的方法，该方法可用于制备与烷基、取代芳基或取代杂环芳基酰化或磺酰化的酰胺。该方法涉及将双叔丁基重氮-1,2-二羧酸酯与(4S)-4-苄基-3-[(S)-三氟甲基-烷基取代的烷酰基]-1,3-噁唑啉-2-酮反应，得到双叔丁基1-(1S,2S)-[(4S)-4-苄基-2-氧代-1,3-噁唑啉-3-基-羰基}-三氟甲基-烷基取代的烷基)肼-1,2-二羧酸酯。然后将这种二羧酸酯还原，得到双叔丁基1-(1S,2S)-[三氟甲基-烷基取代的烷基]肼-1-(羟甲基)-1,2-二羧酸酯。最终产物通过酸脱保护，得到(2S,3S)-三氟甲基肼基甲基烷基-1-醇的酸加成盐。将(2S,3S)-三氟-2-肼基甲基烷基-1-醇的酸加成盐在适当金属催化剂存在下氢化，得到氨基醇(2S,3S)-2-氨基三氟甲基烷基-1-醇盐酸盐。
• TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
  申请人：Porte Alexander Michael

  公开号：US20090221711A1

  公开（公告）日：2009-09-03

  A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R 1 -R 7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

  提供了公式（I）的化合物，或其药学上可接受的盐和/或水合物或前药，其中公式（I）具有结构：其中R1-R7在此定义。这些化合物在治疗以下疾病的药物中有用，所述疾病选自阿尔茨海默病，淀粉样血管病，脑淀粉样血管病，全身性淀粉样变性，荷兰型遗传性脑出血伴有淀粉样沉积，包涵体肌病，轻度认知障碍（MCI）和唐氏综合症。
• PRODUCTION OF CHIRALLY PURE AMINO ALCOHOL INTERMEDIATES, DERIVATIVES THEREOF, AND USES THEREOF
  申请人：Sellstedt John

  公开号：US20100016639A1

  公开（公告）日：2010-01-21

  A method of selectively preparing a chiral 2S-amino alcohol useful in preparation of an amide sulfonated or acylated with alkyl, substituted aryl or substituted heteroaryl is described. The method involves reacting a di-tert-butyl diazene-1,2-dicarboxylate with a (4S)-4-benzyl-3-[(S)-trifluoromethyl-alkyl substituted alkanoyl]-1,3-oxazolidin-2-one to afford a di-tert-butyl 1-(1S,2S)-([(4S)-4-benzyl-2-oxo-1,3-oxazolidine-3-yl]-carbonyl}-trifluoromethyl-alkyl substituted alkyl)hydrazine-1,2-dicarboxylate. This dicarboxylate is then reduced to yield di-tert-butyl 1-(1S,2S)-[trifluoromethyl-alkyl substituted alkyl]hydrazine-1-(hydroxymethyl)-1,2-dicarboxylate. The resulting product is deblocked with an acid to yield the acid addition salt of (2S,3S)-trifluoro-hydrazino-methyl alkan-1-ol. The acid addition salt of (2S,3S)-trifluoro-2-hydrazino-methyl alkan-1-ol is hydrogenated in the presence of a suitable metal catalyst to yield the amino alcohol (2S,3S)-2-amino-trifluoro-methyl alkan-1-ol HCl.

  本文介绍了一种选择性制备手性2S-氨基醇的方法，该方法可用于制备与烷基、取代芳基或取代杂环基乙酰化或磺化的酰胺。该方法涉及将双叔丁基重氮-1,2-二甲酯与(4S)-4-苄基-3-[(S)-三氟甲基-烷基取代的酰基]-1,3-噁唑啉-2-酮反应，得到双叔丁基1-(1S,2S)-[(4S)-4-苄基-2-氧代-1,3-噁唑啉-3-基]-酰基-三氟甲基-烷基取代的烷基)肼-1,2-二甲酯。然后将该二甲酯还原，得到双叔丁基1-(1S,2S)-[三氟甲基-烷基取代的烷基]肼-1-(羟甲基)-1,2-二甲酯。将得到的产物用酸去保护基，得到(2S,3S)-三氟甲基肼甲基烷-1-醇的酸加成盐。将(2S,3S)-三氟甲基肼甲基烷-1-醇的酸加成盐在适当的金属催化剂存在下加氢，得到氨基醇(2S,3S)-2-氨基-三氟甲基烷基烷-1-醇盐酸盐。